65 filings
8-K
BCYC
Bicycle Therapeutics Plc
2 May 24
Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results
7:06am
8-K
BCYC
Bicycle Therapeutics Plc
18 Apr 24
Entry into a Material Definitive Agreement
7:00am
8-K
BCYC
Bicycle Therapeutics Plc
20 Feb 24
Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results
7:05am
8-K
BCYC
Bicycle Therapeutics Plc
14 Dec 23
Bicycle Therapeutics Provides Data Updates for Three Clinical Programs and Strategy Overview at First R&D Day
7:05am
8-K
BCYC
Bicycle Therapeutics Plc
2 Nov 23
Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2023 Financial Results and Announces Upcoming R&D Day
7:05am
8-K
2141rbcwn7fl7ryrk 2q
11 Sep 23
Bicycle Therapeutics Announces Expedited Development Plan for BT8009 in Metastatic Bladder Cancer
7:05am
8-K
cwaj0v ooq3uhh7fh9
3 Aug 23
Bicycle Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
6:59am
8-K
j4jhbu
13 Jul 23
Entry into a Material Definitive Agreement
4:27pm
8-K
619sq
23 Jun 23
Departure of Directors or Certain Officers
7:43am
8-K
c8uhrmmvxqhdag obpn
14 Jun 23
Submission of Matters to a Vote of Security Holders
8:33am
8-K
1i47ms2zz
26 May 23
Other Events
5:26pm
8-K
v823m06f52
10 May 23
Bayer and Bicycle Therapeutics Enter Strategic Collaboration for Development of Novel Targeted Radionuclide Therapies in Oncology
7:06am
8-K
6kbq4ls0ei48ys4r
4 May 23
Bicycle Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
7:30am
8-K
e77w4
3 Apr 23
Bicycle Therapeutics Enhances Leadership Team with Key Appointments
7:05am
8-K
4z8ui
28 Mar 23
Bicycle Therapeutics Announces a Strategic Collaboration with Novartis to Discover, Develop and Commercialize Bicycle® Radio-Conjugates
7:07am
8-K
ezhwor07wtkt0c
28 Feb 23
Bicycle Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
7:06am
8-K
sx03 2356uxoh1dk
14 Feb 23
Bicycle Therapeutics Announces Phase I Dose Escalation Results from Ongoing Phase I/II Study of BT8009
10:26am
8-K
yyihiblex80vqhzy4
23 Jan 23
Departure of Directors or Certain Officers
7:31am
8-K
opb22dlp
8 Nov 22
Bicycle Therapeutics Announces First Patient Dosed in BT8009 Phase II Expansion Cohorts and Provides Program Update
7:07am
8-K
96kcj9
3 Nov 22
Bicycle Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
7:08am